刘光明　丘仲柳　陈世豪　赖天寿　谭柏松　李健茹

【摘要】 目的：探析肿瘤标志物在肺癌临床诊断中的应用价值。方法：选取2014年8月-2017年8月本院收治的100例肺癌患者为观察1组，以45例肺部良性病变患者为观察2组，以同期到本院接受检查的50名健康人为对照组。三组研究对象均接受癌胚抗原（CEA）、糖类抗原125（CA125）、细胞角蛋白19片段抗原21-1（CYFRA21-1）、神经元特异性烯醇化酶（NSE）、胃泌素释放肽前体（Pro-GRP）、促血管生成素-2（Ang-2）肿瘤标志物检查，对三组的检查结果及肿瘤标志物的诊断价值进行对比分析。结果：观察1组CEA、CA125、CYFRA21-1、NSE、Pro-GRP、Ang-2检测水平均明显高于观察2组和对照组（P<0.05）。在肺癌分期的诊断上：肺癌Ⅳ期患者六种肿瘤标志物的检测水平均明显高于肺癌Ⅲ期患者，且肺癌Ⅲ期患者的肿瘤标志物检测值均高于Ⅲ期和Ⅰ期患者（P<0.05）。结论：在肺癌的临床诊断中，肿瘤标志物起到较好的诊断效果，可根据肿瘤标志物的检测结果对病情的发展情况、临床分期、是否发生淋巴结转移和治疗后是否复发进行诊断，可降低临床漏诊、误诊。

【关键词】 肿瘤标志物； 肺癌； 淋巴转移

Application Effect of Tumor Markers in Clinical Diagnosis of Lung Cancer/LIU Guangming，QIU Zhongliu，CHEN Shihao，et al.//Medical Innovation of China，2018，15（27）：0-057

【Abstract】 Objective：To explore the application effect of tumor markers in clinical diagnosis of lung cancer.Method：A total of 100 patients with lung cancer obtained treatment in our hospital form August 2014 to August 2017 were selected as Group 1，45 patients with benign pulmonary disease were selected as Group 2 and 50 healthy people were received health examination in our hospital as control group.CEA，CA125，CYFRA21-1，NSE，Pro-GRP and Ang-2 tumor marker examinations were examined among three groups，the results and joint diagnose value of tumor markers were compared and analyzed.Result：The detection levels of CEA，CA125，CYFRA21-1，NSE，Pro-GRP and Ang-2 of Group 1 were significantly higher than those of Group 2 and control group（P<0.05）.Regarding the diagnosis of lung cancer staging，the detection levels of six types of tumor markers of patients in Ⅳstaging of lung cancer were significantly higher than those of patients in Ⅲ staging of lung cancer，and tumor markers detection levels of Ⅲ staging were also higher than those of patients in Ⅲ and Ⅰ staging of lung cancer（P<0.05）.Conclusion：Tumor markers give effective diagnosis basis in clinical diagnosis of lung cancer，according to which disease progression，clinical stages，whether there is lymphatic metastasis and whether lung cancer is recurrent or not after treatment can be judged.Thus，tumor marker is able to reduce clinical misdiagnosis and missed diagnosis.

【Key words】 Tumor marker； Lung cancer； Lymphatic metastasis

First-authors address：Jiangmen Xinhui Peoples Hospital，Jiangmen 529100，China

doi：10.3969/j.issn.1674-4985.2018.27.014

近年來，肺癌的发病率呈现逐年递增的发展趋势，且该病的死亡率较高，已经成为对人们生命健康造成严重威胁的最大恶性肿瘤之一。诱发肺癌的因素较多，大量研究和资料表明，长期大量吸烟与肺癌的发生有极为密切的联系，长期吸烟患肺癌的可能性是不吸烟者的10～20倍，而开始吸烟的年龄越小，肺癌的患病概率越高[1-2]。医学专家和学者近年来将研究的重点放在肿瘤分子生物学上，发现很多肿瘤标志物可提示肿瘤的组织类型和肿瘤来源，在肺癌的检测、诊断和预后判定上均有非常重要的临床价值[3-4]。但目前尚未找到具有较高特异性和敏感性的单一肿瘤标志物，故临床上往往采用联合检测，以保障检查结果的准确性[5-6]。本研究以肺癌患者、肺部良性病变患者和健康人为主要研究对象，对肿瘤标志物的检测结果进行汇总和对比，做到早发现、早诊断、早治疗，以延长患者的无进展生存期，提升其生存质量。……